Eton Pharma Near Term Catalysts Vanish
Source: SeekingAlpha
2025-07-15 09:33:40 ET
Eton Pharmaceuticals (NASDAQ: ETON ) operates in the tiny ultra-rare disease niche. I have previously written a deep dive on ETON's business model , in which I argued they are likely to dominate the "orphan drug" space, so for anyone interested in a full description of the company, including risks and valuation, that might be a good place to start....
Read the full article on Seeking Alpha
For further details see:
Eton Pharma Near Term Catalysts Vanish
Eton Pharmaceutcials Inc.
NASDAQ: ETON
ETON Trading
0.97% G/L:
$18.69 Last:
83,953 Volume:
$19.08 Open:
ETON Latest News
March 03, 2026 04:30:00 pm
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 02, 2026 07:27:44 am
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
February 25, 2026 01:47:00 pm
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution
February 20, 2026 06:50:00 am
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
ETON Stock Data
$408,699,233
22,518,684
14.05%
24
N/A
Pharmaceuticals
Healthcare
US
Deer Park
